Polymorphism and crystallization of active pharmaceutical ingredients (APIs)

Current Medicinal Chemistry

Volumn 16, Issue 7, 2009, Pages 884-905

  Lu, Jie ^a   Rohani, Sohrab ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Active pharmaceutical ingredients (APIs); Control; Crystallization; Discovery; Polymorphism; Pseudopolymorphism

Indexed keywords

ABECARNIL; ACTIVE PHARMACEUTICAL INGREDIENT; CARBAMAZEPINE; CIMETIDINE; DIFLUNISAL; DRUG ADDITIVE; EFLUCIMIBE; ESTRADIOL; FAMOTIDINE; FLUCONAZOLE; INDOMETACIN; MEBENDAZOLE; NABUMETONE; NIFEDIPINE; PARACETAMOL; PHENYLBUTAZONE; PROGESTERONE; RIBAVIRIN; RITONAVIR; SERTRALINE; SODIUM CHLORIDE; STAVUDINE; STEARIC ACID; SULFAMERAZINE; SULFAMETHOXAZOLE; SULFATHIAZOLE; SULINDAC; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CHEMICAL REACTION KINETICS; CHEMICAL STRUCTURE; CRYSTAL; CRYSTALLIZATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; PHARMACEUTICAL ENGINEERING; REVIEW; SOLID STATE; THERMODYNAMICS;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; PHARMACEUTICAL PREPARATIONS;

EID: 65649125667     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787549299     Document Type: Review

References (219)

1. Morissette, S.L.; Almarsson, Ö.; Peterson, M.L.; Remenar, J.F.; Read, M.J.; Lemmo, A.V.; Ellis, S.; Cima, M.J.; Gardner, C.R. High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Deliv. Rev., 2004, 56, 275-300.
2. Byrn, S.R.; Pfeiffer, R.R.; Stowell, J.G. Solid-State Chemistry of Drugs, SSCI: West Lafayette, 1999.
3. Shekunov, B. Yu.; York, P. Crystallization processes in pharmaceutical technology and drug delivery design. J. Cryst. Growth, 2000, 211, 122-36.
4. Bernstein, J. Polymorphism in Molecular Crystals, Oxford University Press: New York, 2002.
5. Datta, S.; Grant, D.J.W. Crystal structures of drugs: Advances in determination, prediction and engineering. Nat. Rev. Drug Discov., 2004, 3, 42-57.
6. Rodríguez-Spong, B.; Price, C.P.; Jayasankar, A.; Matzger, A.J.; Rodríguez-Hornedo, N. General principles of pharmaceutical solid polymorphism: A supramolecular perspective. Adv. Drug Deliv. Rev., 2004, 56, 241-74.
7. Dunitz, J.D.; Bernstein, J. Disappearing polymorphs. Accounts Chem. Res., 1995, 28, 193-200.
8. Bernstein, J.; Davey, R.J.; Henck, J.O. Concomitant polymorphs. Angew. Chem. Int. Ed., 1999, 38, 3440-61.
9. Grant, D.J.W. In Polymorphism in Pharmaceutical Solids; Brittain, H.G., Ed.; Marcel Dekker: New York, 1999, pp. 1-33.
10. Vippagunta, S.R.; Brittain, H.G.; Grant, D.J.W. Crystalline solids. Adv. Drug Deliv. Rev., 2001, 48, 3-26.
11. Sirota, N.N. Certain problems of polymorphism (I). Cryst. Res. Technol., 1982, 17, 661-91.
12. Payne, R.S.; Rowe, R.C.; Roberts, R.J.; Charlton, M.H.; Docherty, R. Potential polymorphs of aspirin. J. Comput. Chem., 1999, 20, 262-73.
13. Schwartzman, G. Does aspirin exist in polymorphic states? J. Pharm. Pharmacol., 1972, 24, 169-70.
14. Doherty, C.; York, P. Frusemide crystal forms - solid-state and physicochemical analyses. Int. J. Pharm., 1988, 47, 141-55.
15. Rodríguez-Caabeiro, F.; Criado-Fornelio, A.; Jimenez-Gonzalez, A.; Guzman, L.; Igual, A.; Perez, A.; Pujol, M. Experimental chemotherapy and toxicity in mice of three mebendazole polymorphic forms. Chemotherapy, 1987, 33, 266-71.
16. Swanepoel, E.; Liebenberg, W.; de Villiers, M.M. Quality evaluation of generic drugs by dissolution test: Changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. Eur. J. Pharm. Biopharm., 2003, 55, 345-9.
17. Sun, C.; Grant, D.J.W. Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm. Res., 2001, 18, 274-80.
18. Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J. Ritonavir: An extraordinary example of conformational polymorphism. Pharm. Res., 2001, 18, 859-66.
19. Chemburkar, S.R.; Bauer, J.; Deming, K.; Spiwek, H.; Patel, K.; Morris, J.; Henry, R.; Spanton, S.; Dziki, W.; Porter, W.; Quick, J.; Bauer, P.; Donaubauer, J.; Narayanan, B.A.; Soldani, M.; Riley, D.; McFarland, K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process Res. Dev., 2000, 4, 413-7.
20. Nangia, A.; Desiraju, G.R. Pseudopolymorphism: Occurrences of hydrogen bonding organic solvents in molecular crystals. Chem. Commun., 1999, 605-6.
21. Pedireddi, V.R.; PrakashaReddy, J. Supramolecular pseudopolymorphs: double helix and planar structures with channels. Tetrahedron Lett., 2003, 44, 6679-81.
22. Morris, K.R. In Polymorphs in Pharmaceutical Solids; Brittain, H.G., Ed.; Marcel Dekker: New York, 1999, pp. 125-181.
23. Khankari, R.K.; Grant, D.J.W. Pharmaceutical hydrates. Thermochim. Acta, 1995, 248, 61-79.
24. Bingham, A.L.; Hughes, D.S.; Hursthouse, M.B.; Lancaster, R.W.; Tavener, S.; Threlfall, T.L. Over one hundred solvates of sulfathiazole. Chem. Commun., 2001, 603-4.
25. Infantes, L.; Motherwell, S. Water clusters in organic molecular crystals. Cryst. Eng. Commun., 2002, 4, 454-61.
26. Gillon, A.L.; Feeder, N.; Davey, R.J.; Storey, R. Hydration in molecular crystals - a Cambridge Structural Database analysis. Cryst. Growth Des., 2003, 3, 663-73.
27. Bechtloff, B.; Nordhoff, S.; Ulrich, J. Pseudopolymorphs in industrial use. Cryst. Res. Technol., 2001, 36, 1315-28.
28. Grant, D.J.W.; Higuchi, T. Solubility Behavior of Organic Compounds, Wiley: New York, 1990.
29. Agbada, C.O.; York, P. Dehydration of theophylline monohydrate powder: effects of particle size and sample weight. Int. J. Pharm., 1994, 106, 33-40.
30. Liu, H.B.; Chen, Y.Q.; Zhang, X.C. Characterization of anhydrous and hydrated pharmaceutical materials with THz time-domain spectroscopy. J. Pharm. Sci., 2007, 96, 927-34.
31. Stahl, P.H. In Towards Better Safety of Drugs and Pharmaceutical Products; Braimer, D.D., Ed.; Elsevier/North Holland Biomedical Press: Amsterdam, 1980.
32. Giron, D.; Goldbronn, C.; Mutz, M.; Pfeffer, S.; Piechon, P.; Schwab, P. Solid-state characterizations of pharmaceutical hydrates. J. Thermal Anal. Cal., 2002, 68, 453-65.
33. Morris, K.R.; Rodríguez-Hornedo, N. In Encyclopedia of Pharmaceutical Technology; Swarbrick, J.; Boylan, J.C., Eds.; Marcel Dekker: New York, 1993, pp. 393-440.
34. Florey, K. Analytical Profiles of Drug Substances, Academic: New York, 1973.
35. Sun, C.; Zhou, D.; Grant, D.J.W.; Young, V.G.Jr. Theophylline monohydrate. Acta Cryst. E, 2002, 58, 368-70.
36. Sugawara, Y.; Kamiya, N.; Iwasaki, H.; Ito, T.; Satow, Y. Humidity controlled reversible structure transition of disodium adenosine 5′-triphosphate between dihydrate and trihydrate in a single crystal state. J. Am. Chem. Soc., 1991, 113, 5440-5.
37. Ahlqvist, M.U.A.; Taylor, L.S. Water dynamics in channel hydrates investigated using H/D exchange. Int. J. Pharm., 2002, 241, 253-61.
38. Stahl, P.H.; Nakano, M. In Handbook of Pharmaceutical Salts: Properties, Selection, and Use; Stahl, P.H.; Wermuth, C.G., Eds.; Wiley: Weinheim, 2002, pp. 83-116.
39. Berge, S.M.; Bighley, L.D.; Monkhouse, D.C. Pharmaceutical salts. J. Pharm. Sci., 1977, 66, 1-19.
40. Gould, P.L. Salt selection for basic drugs. Int. J. Pharm., 1986, 33, 201-17.
41. Tong, W.; Whitesell, G. In situ salt screening - a useful technique for discovery support and preformulation studies. Pharm. Dev. Technol., 1998, 3, 215-23.
42. Morris, K.R.; Fakes, M.G.; Thakur, A.B.; Newman, A.W.; Singh, A.K.; Venit, J.J.; Spagnuolo, C.J.; Serajuddin, A.T.M. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm., 1994, 105, 209-17.
43. Neau, S.H. In Water-Insoluble Drug Formulation; Liu, R., Ed.; Interpharm Press: Denver, 2000, pp. 405-425.
44. Pudipeddi, M.; Serajuddin, A.T.M.; Grant, D.J.W.; Stahl, P.H. In Handbook of Pharmaceutical Salts, Properties, Selection, and Use; Stahl, P.H.; Wermuth, C.G., Eds.; Wiley: Weinheim, 2002, pp. 19-39.
45. Giron, D.; Grant, D.J.W. In Handbook of Pharmaceutical Salts: Properties, Selection, and Use; Stahl, P.H.; Wermuth, C.G., Eds.; Wiley: Weinheim, 2002, pp. 41-81.
46. Mirmehrabi, M.; Rohani, S.; Murthy, K.S.K.; Radatus, B. Characterization of tautomeric forms of ranitidine hydrochloride: Thermal analysis, solid-state NMR, X-ray. J. Cryst. Growth, 2004, 260, 517-26.
47. Mirmehrabi, M.; Rohani, S. An approach to solvent screening for crystallization of polymorphic pharmaceuticals and fine chemicals. J. Pharm. Sci., 2005, 94, 1560-76.
48. Almarsson, Ö.; Hickey, M.B.; Peterson, M.L.; Morissette, S.L.; McNulty, C.; Soukasene, S.; Tawa, M.; MacPhee, M.; Remenar, J.F. High-throughput surveys of crystal form diversity of highly polymorphic pharmaceutical compounds. Cryst. Growth Des., 2003, 3, 927-33.
49. Remenar, J.F.; MacPhee, J.M.; Larson, B.K.; Tyagi, V.A.; Ho, J.H.; McIlroy, D.A.; Hickey, M.B.; Shaw, P.B.; Almarsson, Ö. Salt selection and simultaneous polymorphism assessment via high-throughput crystallization: The case of sertraline. Org. Process Res. Dev., 2003, 7, 990-6.
50. Aakeroy, C.B.; Fasulo, M.E.; Desper, J. Cocrystal or salt: Does it really matter? Mol. Pharm., 2007, 4, 317-22.
51. Vishweshwar, P.; McMahon, J.A.; Bis, J.A.; Zaworotko, M.J. Pharmaceutical co-crystal. J. Pharm. Sci., 2006, 95, 499-516.
52. Basavoju, S.; Bostrom, D.; Velaga, S.P. Indomethacin-saccharin cocrystal: Design, synthesis and preliminary pharmaceutical characterization. Pharm. Res., 2008, 25, 530-41.
53. Childs, S.L.; Hardcastle, K.I. Cocrystals of piroxicam with carboxylic acids. Cryst. Growth Des., 2007, 7, 1291-304.
54. Bucar, D.K.; Henry, R.F.; Lou, X.C.; Duerst, R.W.; Borchardt, T.B.; MacGillivray, L.R.; Zhang, G.G.Z. Co-crystals of caffeine and hydroxy-2-naphthoic acids: Unusual formation of the carboxylic acid dimer in the presence of a heterosynthon. Mol. Pharm., 2007, 4, 339-46.
55. Fernandez-Lopez, S.; Kim, H.S.; Choi, E.C.; Delgado, M.; Granja, J.R.; Khasanov, A.; Kraehenbuehl, K.; Long, G.; Weinberger, D.A.; Wilcoxen, K.M.; Ghadiri, M.R. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature, 2001, 412, 452-5.
56. Trask, A.V. An overview of pharmaceutical cocrystals as intellectual property. Mol. Pharm., 2007, 4, 301-9.
57. Walsh, R.D.B.; Bradner, M.W.; Fleishman, S.; Morales, L.A.; Moulton, B.; Rodrígues-Hornedo, N.; Zaworotko, M.J. Crystal engineering of the composition of pharmaceutical phases. Chem. Commun., 2003, 186-7.
58. Seefeldt, K.; Miller, J.; Alvarez-Núñez, F.; Rodríguez-Hornedo, N. Crystallization pathways and kinetics of carbamazepinenicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies. J. Pharm. Sci., 2007, 96, 1147-58.
59. Chadwick, K.; Davey, R.; Cross, W. How does grinding produce co-crystals? Insights from the case of benzophenone and diphenylamine. Cryst. Eng. Comm., 2007, 9, 732-4.
60. Vishweshwar, P.; McMahon, J.A.; Peterson, M.L.; Hickey, M.B.; Shattock, T.R.; Zaworotko, M.J. Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients. Chem. Commun., 2005, 4601-3.
61. Chiarella, R.A.; Davey, R.J.; Peterson, M.L. Making co-crystals - The utility of ternary phase diagrams. Cryst. Growth Des., 2007, 7, 1223-6.
62. Yu, L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv. Drug Deliv. Rev., 2001, 48, 27-42.
63. Taylor, L.S.; Zografi, G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res., 1997, 14, 1691-8.
64. Hancock, B.C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci., 1997, 86, 1-12.
65. Hancock, B.C.; Parks, M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res., 2000, 17, 397-404.
66. Pan, X.H.; Julian, T.; Augsburger, L. Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: A case study with indomethicin. Drug Dev. Ind. Pharm., 2008, 34, 221-31.
67. Chono, S.; Takeda, E.; Seki, T.; Morimoto, K. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin. Int. J. Pharm., 2008, 347, 71-8.
68. Vasconcelos, T.; Sarmento, B.; Costa, P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today, 2007, 12, 1068-75.
69. Hancock, B.C. Disordered drug delivery: Destiny, dynamics and the Deborah number. J. Pharm. Pharmacol., 2002, 54, 737-46.
70. Singhal, D.; Curatolo, W. Drug polymorphism and dosage form design: A practical perspective. Adv. Drug Deliv. Rev., 2004, 56, 335-47.
71. Shamblin, S.L.; Hancock, B.C.; Pikal, M.J. Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses. Pharm. Res., 2006, 23, 2254-68.
72. Lehto, V.P.; Laine, E. Assessment of physical stability of different forms of cefadroxil at high humidities. Int. J. Pharm., 1998, 163, 49-62.
73. Matteucci, M.E.; Brettmann, B.K.; Rogers, T.L.; Elder, E.J.; Williams, R.O.; Johnston, K.P. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol. Pharm., 2007, 4, 782-93.
74. Muller, M.; Meier, U.; Kessler, A.; Mazzotti, M. Experimental study of the effect of process parameters in the recrystallization of an organic compound using compressed carbon dioxide as antisolvent. Ind. Eng. Chem. Res., 2000, 39, 2260-8.
75. Shmeis, R.A.; Wang, Z.R.; Krill, S.L. A mechanistic investigation of an amorphous pharmaceutical and its solid dispersions, part I: A comparative analysis by thermally stimulated depolarization current and differential scanning calorimetry. Pharm. Res., 2004, 21, 2025-30.
76. Liu, J.S. Physical characterization of pharmaceutical formulations in frozen and freeze-dried solid states: Techniques and applications in freeze-drying development. Pharm. Dev. Technol., 2006, 11, 3-28.
77. Chan, H.K.; Clark, A.R.; Feeley, J.C.; Kuo, M.C.; Lehrman, S.R.; Pikal-Cleland, K.; Miller, D.P.; Vehring, R.; Lechuga-Ballesteros, D. Physical stability of salmon calcitonin spray-dried powders for inhalation. J. Pharm. Sci., 2004, 93, 792-804.
78. Hyvönen, S.; Peltonen, L.; Karjalainen, M.; Hirvonen, J. Effect of nanoprecipitation on the physicochemical properties of low molecular weight poly(l-lactic acid) nanoparticles loaded with salbutamol sulphate and beclomethasone dipropionate. Int. J. Pharm., 2005, 295, 269-81.
79. Yu, L.; Mishra, D.S.; Rigsbee, D.R. Determination of the glass properties of D-mannitol using sorbitol as an impurity. J. Pharm. Sci., 1998, 87, 774-7.
80. Gupta, M.K.; Vanwert, A.; Bogner, R.H. Formation of physically stable amorphous drugs by milling with neusilin. J. Pharm. Sci., 2003, 92, 536-51.
81. Mirza, S.; Miroshnyk, I.; Heinämäki, J.; Christiansen, L.; Karjalainen, M.; Yliruusi, J. Influence of solvents on the variety of crystalline forms of erythromycin. AAPS Pharm. Sci., 2003, 5, A12.
82. Chiou, W.L.; Riegelman, S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci., 1971, 60, 1281-302.
83. Saleki-Gerhardt, A.; Stowell, J.G.; Byrn, S.R.; Zografi, G. Hydration and dehydration of crystalline and amorphous forms of raffinose. J. Pharm. Sci., 1995, 84, 318-23.
84. Li, Y.; Han, J.; Zhang, G.G.Z.; Grant, D.J.W.; Suryanarayanan, R. In situ dehydration of carbamazepine dihydrate: A novel technique to prepare amorphous anhydrous carbamazepine. Pharm. Dev. Technol., 2000, 5, 257-66.
85. Prigogine, I. Introduction to Thermodynamics of Irreversible Processes, Charles C. Thomas, Springfield: Illinois, 1955.
86. Burger, A.; Ramberger, R. Polymorphism of pharmaceuticals and other molecular crystals. 1. Theory of thermodynamic rules. Mikrochim. Acta, 1979, 2, 259-71.
87. Burger, A.; Ramberger, R. Polymorphism of pharmaceuticals and other molecular crystals. 2. Applicability of thermodynamic rules. Mikrochim. Acta, 1979, 2, 273-316.
88. Henck, J.O.; Kuhnert-Brandstatter, M. Demonstration of the terms enantiotropy and monotropy in polymorphism research exemplified by flurbiprofen. J. Pharm. Sci., 1999, 88, 103-8.
89. Grunenberg, A.; Henck, J.O.; Siesler, H.W. Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. Int. J. Pharm., 1996, 129, 147-58.
90. Morris, K.R.; Griesser, U.J.; Eckhardt, C.J.; Stowell, J.G. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv. Drug Deliv. Rev., 2001, 48, 91-114.
91. Sato, K. Polymorphic transformations in crystal growth. J. Phys. D - Appl. Phys., 1993, 26, B77-84.
92. Lohani, S.; Grant, D. In Polymorphism in the Pharmaceutical Industry; Hilfiker, R., Ed.; Wiley-VCH: Weinheim, 2006, pp. 21-40.
93. Tong, H.H.Y.; Shekunov, B.Y.; York, P.; Chow, A.H.L. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharm. Res., 2002, 19, 640-8.
94. Burger, A. Thermodynamic and other aspects of the polymorphism of drug substances. Pharm. Int., 1982, 3, 158-63.
95. Griesser, U.J.; Burger, A.; Mereiter, K. The polymorphic drug substances of the European pharmacopoeia. 9. Physicochemical properties and crystal structure of acetazolamide crystal forms. J. Pharm. Sci., 1997, 86, 352-8.
96. Schmidt, A.C. Solid-state characterization of chloroprocaine hydrochloride. J. Therm. Anal. Calorim., 2005, 81, 291-7.
97. Mullin, J.W. Crystallization, 4th ed.; Butterworth Heinemann: Oxford, 2001.
98. Paxton, T.E.; Sambanis, A.; Rousseau, R.W. Influence of vessel surfaces on the nucleation of protein crystals. Langmuir, 2001, 17, 3076-9.
99. Bonafede, S.J.; Ward, M.D. Selective nucleation and growth of an organic polymorph by ledge-directed epitaxy on a molecular-crystal substrate. J. Am. Chem. Soc., 1995, 117, 7853-61.
100. Threlfall, T. Structural and thermodynamic explanations of Ostwald's rule. Org. Process Res. Dev., 2003, 7, 1017-27
101. Ostwald, W. Studien uber die Bildung und Umwandlung fester Körper. Z. Phys. Chem., 1897, 22, 289-330.
102. Shekunov, B.Yu.; Latham, R.J. Growth anisotropy of N-methylurea crystals in methanol. J. Phys. Chem., 1996, 100, 5464-9.
103. Shekunov, B.Yu.; Grant, D.J.W. In situ optical interferometric studies of the growth and dissolution behavior of paracetamol (acetaminophen). 1. Growth kinetics. J. Phys. Chem. B, 1997, 101, 3973-9.
104. Davey, R.J.; Blagden, N.; Potts, G.D.; Docherty, R. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J. Am. Chem. Soc., 1997, 119, 1767-72
105. Threlfall, T. Crystallization of polymorphs: Thermodynamic insight into the role of solvent. Org. Process Res. Dev., 2000, 4, 384-90.
106. Davey, R.J.; Allen, K.; Blagden, N.; Cross, W.I.; Lieberman, H.F.; Quayle, M.J.; Righini, S.; Seton, L.; Tiddy, G.J.T. Crystal engineering - nucleation, the key step. Cryst. Eng. Commun., 2002, 4, 257-64.
107. Blagden, N.; Davey, R.J.; Rowe, R.; Roberts, R. Disappearing polymorphs and the role of reaction by-products: The case of sulphathiazole. Int. J. Pharm., 1998, 172, 169-77.
108. Gu, C.H.; Young, V.; Grant, D.J.W. Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation. J. Pharm. Sci., 2001, 90, 1878-90.
109. Byrn, S.R.; Pfeiffer, R.R.; Ganey, M.; Hoiberg, C.; Poochikian, G. Pharmaceutical solids - A strategic approach to regulatory considerations. Pharm. Res., 1995, 12, 945-54.
110. Starbuck, C.; Spartalis, A.; Wai, L.; Wang, J.; Fernandez, P.; Lindemann, C.M.; Zhou, G.X.; Ge, Z.H. Process optimization of a complex pharmaceutical polymorphic system via in situ Raman spectroscopy. Cryst. Growth Des., 2002, 2, 515-22.
111. Threlfall, T.L. Analysis of organic polymorphs - A review. Analyst., 1995, 120, 2435-60.
112. Skrdla, P.J.; Antonucci, V.; Crocker, L.S.; Wenslow, R.M.; Wright, L.; Zhou, G. A simple quantitative FT-IR approach for the study of a polymorphic transformation under crystallization slurry conditions. J. Pharm. Biomed. Anal., 2001, 25, 731-9.
113. Datta, S.; Grant, D.J.W. Effect of supersaturation on the crystallization of phenylbutazone polymorphs. Cryst. Res. Technol., 2005, 40, 233-42.
114. Neumann, M.A.; Leusen, F.J.J.; Engel, G.E.; Wilke, S.; Conesa-Moratilla, C. Recent advances in structure solution from powder diffraction data. Int. J. Mod. Phys. B, 2002, 16, 407-14.
115. Harris, K.D.M. New opportunities for structure determination of molecular materials directly from powder diffraction data. Cryst. Growth Des., 2003, 3, 887-95.
116. David, W.I.F.; Shankland, K.; Shankland, N. Routine determination of molecular crystal structures from powder diffraction data. Chem. Commun., 1998, 931-2.
117. Padden, B.E.; Zell, M.T.; Dong, Z.; Schroeder, S.A.; Grant, D.J.W.; Munson, E.J. Comparison of solid-state C-13 NMR spectroscopy and powder X-ray diffraction for analyzing mixtures of polymorphs of neotame. Anal. Chem., 1999, 71, 3325-31.
118. Tanninen, V.P.; Yliruusi, J. X-ray-powder diffraction profile fitting in quantitative-determination of 2 polymorphs from their powder mixture. Int. J. Pharm., 1992, 81, 169-77.
119. Ayala, A.P.; Siesler, H.W.; Boese, R.; Hoffmann, G.G.; Polla, G.I.; Vega, D.R. Solid state characterization of olanzapine polymorphs using vibrational spectroscopy. Int. J. Pharm., 2006, 326, 69-79.
120. Pollanen, K.; Hakkinen, A.; Huhtanen, M.; Reinikainen, S.P.; Karjalainen, M.; Rantanen, J.; Louhi-Kultanen, M.; Nystrom, L. DRIFT-IR for quantitative characterization of polymorphic composition of sulfathiazole. Anal. Chim. Acta, 2005, 544, 108-17.
121. Salari, A.; Young, R.E. Application of attenuated total reflectance FTIR spectroscopy to the analysis of mixtures of pharmaceutical polymorphs. Int. J. Pharm., 1998, 163, 157-66.
122. Reutzel-Edens, S.M. Achieving polymorph selectivity in the crystallization of pharmaceutical solids: Basic considerations and recent advances. Curr. Opin. Drug Discov. Dev., 2006, 9, 806-15.
123. Li, W.Y.; Worosila, G.D.; Wang, W.; Mascaro, T. Determination of polymorph conversion of an active pharmaceutical ingredient in wet granulation using NIR calibration models generated from the premix blends. J. Pharm. Sci., 2005, 94, 2800-6.
124. Sakai, H.; Hosogai, H.; Kawakita, T. Transformation of α-glycine to γ-glycine. J. Cryst. Growth, 1992, 116, 421-6.
125. Yang, X.; Lu, J.; Wang, X.J.; Ching, C.B. Effect of sodium chloride on the nucleation and polymorphic transformation of glycine. J. Cryst. Growth, 2008, 310, 604-11.
126. Lu, J.; Wang, X.J.; Yang, X.; Ching, C.B. Polymorphism and crystallization of famotidine. Cryst. Growth Des., 2007, 7, 1590-8.
127. Garrett, E.R. Prediction of stability of drugs and pharmaceutical preparations. J. Pharm. Sci., 1962, 51, 811-33
128. Ono, T.; ter Horst, J.H.; Jansens, P.J. Quantitative measurement of the polymorphic transformation of L-glutamic acid using in-situ Raman spectroscopy. Cryst. Growth Des., 2004, 4, 465-9
129. Raspail, F.V. Noveau systeme de chimie organique, fonde sur des methodes novelles d'observation; Bailliere: Paris, 1833.
130. Binnig, G.; Quate, C.F.; Gerber, C. Atomic force microscope. Phys. Rev. Lett., 1986, 56, 930-3.
131. Ookubo, N.; Yumoto, S. Rapid surface topography using a tapping mode atomic force microscope. Appl. Phys. Lett., 1999, 74, 2149-51.
132. Florin, E.L.; Moy, V.T.; Gaub, H.E. Adhesion forces between individual ligand-receptor pairs. Science, 1994, 264, 415-7
133. Danesh, A.; Chen, X.Y.; Davies, M.C.; Roberts, C.J.; Sanders, G.H.W.; Tendler, S.J.B.; Williams, P.M.; Wilkins, M.J. The discrimination of drug polymorphic forms from single crystals using atomic force microscopy. Pharm. Res., 2000, 17, 887-90.
134. Sindel, U.; Zimmermann, I. Measurement of interaction forces between individual powder particles using an atomic force microscope. Powder Technol., 2001, 117, 247-54.
135. Tong, H.H.Y.; Shekunov, B.Y.; Chan, J.P.; Mok, C.K.F.; Hung, H.C.M.; Chow, A.H.L. An improved thermoanalytical approach to quantifying trace levels of polymorphic impurity in drug powders. Int. J. Pharm., 2005, 295, 191-9.
136. Vitez, I.M.; Newman, A.W.; Davidovich, M.; Kiesnowski, C. The evolution of hot-stage microscopy to aid solid-state characterizations of pharmaceutical solids. Thermochim. Acta, 1998, 324, 187-96.
137. Bauer-Brandl, A. Polymorphic transitions of cimetidine during manufacture of solid dosage forms. Int. J. Pharm., 1996, 140, 195-206.
138. Sanders, G.H.W.; Roberts, C.J.; Danesh, A.; Murray, A.J.; Price, D.M.; Davies, M.C.; Tendler, S.J.B.; Wilkins, M.J. Discrimination of polymorphic forms of a drug product by localized thermal analysis. J. Microsc. - Oxford, 2000, 198, 77-81.
139. Offerdahl, T.J.; Salsbury, J.S.; Dong, Z.D.; Grant, D.J.W.; Schroeder, S.A.; Prakash, I.; Gorman, E.M.; Barich, D.H.; Munson, E.J. Quantitation of crystalline and amorphous forms of anhydrous neotame using C-13 CPMAS NMR spectroscopy. J. Pharm. Sci., 2005, 94, 2591-605.
140. Geppi, M.; Mollica, G.; Borsacchi, S.; Veracini, C.A. Solid-state NMR studies of pharmaceutical systems. Appl. Spectroscopy Rev., 2008, 43, 202-302.
141. Harris, R.K. Applications of solid-state NMR to pharmaceutical polymorphism and related matters. J. Pharm. Pharmacol., 2007, 59, 225-39.
142. Tishmack, P.A.; Bugay, D.E.; Byrn, S.R. Solid-state nuclear magnetic resonance spectroscopy - pharmaceutical applications. J. Pharm. Sci., 2003, 92, 441-74.
143. Berendt, R.T.; Sperger, D.M.; Isbester, P.K.; Munson, E.J. Solid-state NMR spectroscopy in pharmaceutical research and analysis. Trends Anal. Chem., 2006, 25, 977-84.
144. Nelson, B.N.; Schieber, L.J.; Barich, D.H.; Lubach, J.W.; Offerdahl, T.J.; Lewis, D.H.; Heinrich, J.P.; Munson, E.J. Multiple-sample probe for solid-state NMR studies of pharmaceuticals. Solid State Nucl. Mag., 2006, 29, 204-13.
145. Schmidt, A.C.; Schwarz, I.; Mereiter, K. Polymorphism and pseudopolymorphism of salicaine and salicaine hydrochloride crystal polymorphism of local anaesthetic drugs, part V. J. Pharm. Sci., 2006, 95, 1097-113.
146. Roy, S.; Aitipamula, S.; Nangia, A. Thermochemical analysis of venlafaxine hydrochloride polymorphs 1-5. Cryst. Growth Des., 2005, 5, 2268-76.
147. Trask, A.V.; Motherwell, W.D.S.; Jones, W. Solvent-drop grinding: Green polymorph control of cocrystallisation. Chem. Commun., 2004, 890-1.
148. Ueda, Y.; Iida, Y.; Manabe, H.; Kitamura, M. Control of polymorphs and crystal habit in crystallization of N-2-(1(S)-ethoxycarbonyl- 3-phenylpropyl)-N-6-trifluoroacetyl-L-lysine. Chem. Eng. Res. Des., 2007, 85, 406-9.
149. Kitamura, M. Controlling factors and mechanism of polymorphic crystallization. Cryst. Growth Des., 2004, 4, 1153-9.
150. Khoshkhoo, S.; Anwar, J. Crystallization of polymorphs - The effect of solvent. J. Phys. D - Appl. Phys., 1993, 26, B90-3.
151. Weissbuch, I.; Lahav, M.; Leiserowitz, L. Toward stereochemical control, monitoring, and understanding of crystal nucleation. Cryst. Growth Des., 2003, 3, 125-50.
152. Kamlet, M.J.; Dickinson, C.; Gramstad, T.; Taft, R.W. Linear solvation energy relationships. 16. Dipole dipole contributions to formation-constants of some hydrogen-bonded complexes. J. Org. Chem., 1982, 47, 4971-5.
153. 2. Pharm. Res., 2001, 18, 682-8.
154. 2 solution. Chem. Pharm. Bull., 2005, 53, 1025-8.
155. Moribe, K.; Tozuka, Y.; Yamamoto, K. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation. Adv. Drug Deliv. Rev., 2008, 60, 328-38.
156. Beckmann, W.; Otto, W.; Budde, U. Crystallization of the stable polymorph of hydroxytriendione: Seeding process and effects of purity. Org. Process Res. Dev., 2001, 5, 387-92.
157. Zhou, G.X.; Crocker, L.; Xu, J.; Tabora, J.; Ge, Z.H. In-line measurement of a drug substance via near infrared spectroscopy to ensure a robust crystallization process. J. Pharm. Sci., 2006, 95, 2337-47.
158. Courvoisier, L.; Ndzie, E.; Petit, M.N.; Hedtmann, U.; Sprengard, U.; Coquerel, G. Influence of the process on the mechanisms and the performances of the preferential crystallization: Example with (+/-)-5- (4-bromophenyl)-5-methylhydantoin. Chem. Lett., 2001, 4, 364-5.
159. Tao, J.; Jones, K.J.; Yu, L. Cross-nucleation between D-mannitol polymorphs in seeded crystallization. Cryst. Growth Des., 2007, 7, 2410-4.
160. Rodríguez-Hornedo, N.; Lechuga-Ballesteros, D.; Wu, H.J. Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int. J. Pharm., 1992, 85, 149-62.
161. Rodríguez-Hornedo, N.; Murphy, D. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J. Pharm. Sci., 2004, 93, 449-60.
162. Tanaka, S.; Ataka, M.; Kubota, T.; Soga, T.; Homma, K.; Lee, W.C.; Tanokura, M. The effect of amphiphilic additives on the growth and morphology of Aspergillus niger acid proteinase A crystals. J. Cryst. Growth, 2002, 234, 247-54.
163. Lee, E.H.; Boerrigter, S.X.M.; Rumondor, A.C.F.; Chamarthy, S.P.; Byrn, S.R. Formation and solid-state characterization of a salt-induced metastable polymorph of flufenamic acid. Cryst. Growth Des., 2008, 8, 91-7.
164. He, X.R.; Stowell, J.G.; Morris, K.R.; Pfeiffer, R.R.; Li, H.; Stahly, G.P.; Byrn, S.R. Stabilization of a metastable polymorph of 4-methyl-2-nitroacetanilide by isomorphic additives. Cryst. Growth Des., 2001, 1, 305-12.
165. Mirmehrabi, M.; Rohani, S. Polymorphic behavior and crystal habit of an anti-viral/HIV drug: Stavudine. Cryst. Growth Des., 2006, 6, 141-9.
166. Lang, M.D.; Grzesiak, A.L.; Matzger, A.J. The use of polymer heteronuclei for crystalline polymorph selection. J. Am. Chem. Soc., 2002, 124, 14834-5.
167. Price, C.P.; Grzesiak, A.L.; Matzger, A.J. Crystalline polymorph selection and discovery with polymer heteronuclei. J. Am. Chem. Soc., 2005, 127, 5512-7.
168. Ng, J.D.; Gavira, J.A.; Garcia-Ruiz, J.M. Protein crystallization by capillary counterdiffusion for applied crystallographic structure determination. J. Struct. Biol., 2003, 142, 218-31.
169. Chyall, L.J.; Tower, J.M.; Coates, D.A.; Houston, T.L.; Childs, S.L. Polymorph generation in capillary spaces: The preparation and structural analysis of a metastable polymorph of nabumetone. Cryst. Growth Des., 2002, 2, 505-10.
170. Childs, S.L.; Chyall, L.J.; Dunlap, J.T.; Coates, D.A.; Stahly, B.C.; Stahly, G.P. A metastable polymorph of metformin hydrochloride: Isolation and characterization using capillary crystallization and thermal microscopy techniques. Cryst. Growth Des., 2004, 4, 441-9.
171. Ha, J.M.; Wolf, J.H.; Hillmyer, M.A.; Ward, M.D. Polymorph selectivity under nanoscopic confinement. J. Am. Chem. Soc., 2004, 126, 3382-3.
172. Hooks, D.E.; Fritz, T.; Ward, M.D. Epitaxy and molecular organization on solid substrates. Adv. Mater., 2001, 13, 227-41.
173. Mitchell, C.A.; Yu, L.; Ward, M.D. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates. J. Am. Chem. Soc., 2001, 123, 10830-9.
174. Hiremath, R.; Varney, S.W.; Swift, J.A. Selective growth of a less stable polymorph of 2-iodo-4-nitroaniline on a self-assembled monolayer template. Chem. Commun., 2004, 2676-7.
175. Garetz, B.A.; Aber, J.E.; Goddard, N.L.; Young, R.G.; Myerson, A.S. Nonphotochemical, polarization-dependent, laser-induced nucleation in supersaturated aqueous urea solutions. Phys. Rev. Lett., 1996, 77, 3475-6.
176. Zaccaro, J.; Matic, J.; Myerson, A.S.; Garetz, B.A. Nonphotochemical, laser-induced nucleation of supersaturated aqueous glycine produces unexpected gamma-polymorph. Cryst. Growth Des., 2001, 1, 5-8.
177. Peterson, M.L.; Morissette, S.L.; McNulty, C.; Goldsweig, A.; Shaw, P.; Lequesne, M.; Monagle, J.; Encina, N.; Marchionna, J.; Gonzalez-Zugasti, A.; Gonzalez-Zugasti, J.; Lemmo, A.V.; Cima, S.J.; Cima, M.J.; Almarsson, Ö. Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J. Am. Chem. Soc., 2002, 124, 10958-9.
178. Gardner, C.R.; Almarsson, Ö.; Chen, H.; Morissette, S.L.; Peterson, M.L.; Zhang, Z.; Wang, S.; Lemmo, A.V.; Gonzales-Zugasti, J.; Monagle, J.; Marchionna, J.; Ellis, S.J.; McNulty, C.; Johnson, A.; Levinson, D.; Cima, M.J. Application of high-throughput technologies to drug substance and drug product development. Comput. Chem. Eng., 2004, 28, 943-53.
179. Maddox, J. Crystals from 1st principles. Nature, 1988, 335, 201.
180. Dunitz, J.D. Are crystal structures predictable? Chem. Commun., 2003, 545-8.
181. Motherwell, W.D.S.; Ammon, H.L.; Dunitz, J.D.; Dzyabchenko, A.; Erk, P.; Gavezzotti, A.; Hofmann, D.W.M.; Leusen, F.J.J.; Lommerse, J.P.M.; Mooij, W.T.M.; Price, S.L.; Scheraga, H.; Schweizer, B.; Schmidt, M.U.; van Eijck, B.P.; Verwer, P.; Williams, D.E. Crystal structure prediction of small organic molecules: A second blind test. Acta Cryst. B, 2002, 58, 647-61.
182. Kitaigorodsky, A.I. Molecular Crystals and Molecules, Academic Press: New York, 1973.
183. Florence, A.J.; Johnston, A.; Price, S.L.; Nowell, H.; Kennedy, A.R.; Shankland, N. An automated parallel crystallization search for predicted crystal structures and packing motifs of carbamazepine. J. Pharm. Sci., 2006, 95, 1918-30.
184. Gavezzotti, A. Computer simulations of organic solids and their liquid-state presursors. Faraday Discuss, 1997, 106, 63-77.
185. Cross, W.I.; Blagden, N.; Davey, R.J.; Pritchard, R.G.; Neumann, M.A.; Roberts, R.J.; Rowe, R.C. A whole output strategy for polymorph screening: Combining crystal structure prediction, graph set analysis, and targeted crystallization experiments in the case of diflunisal. Cryst. Growth Des., 2003, 3, 151-8.
186. Beckmann, W. Nucleation phenomena during the crystallization and precipitation of abecarnil. J. Cryst. Growth, 1999, 198/ 199, 1307-14.
187. Peterson, M.L.; McIlroy, D.; Shaw, P.; Mustonen, J.P.; Oliveira, M.; Almarsson, Ö. Crystallization and transformation of acetaminophen trihydrate. Cryst. Growth Des., 2003, 3, 761-5
188. Gracin, S.; Rasmuson, Å.C. Polymorphism and crystallization of p-aminobenzoic acid. Cryst. Growth Des., 2004, 4, 1013-23.
189. Teychene, S.; Autret, J.M.; Biscans, B. Crystallization of eflucimibe drug in a solvent mixture: Effects of process conditions on polymorphism. Cryst. Growth Des., 2004, 4, 971-7
190. Variankaval, N.E.; Jacob, K.I.; Dinh, S.M. Characterization of crystal forms of β-estradiol - Thermal analysis, Raman microscopy, X-ray analysis and solid-state NMR. J. Cryst. Growth, 2000, 217, 320-31.
191. Jones, H.P.; Davey, R.J.; Cox, B.G. Crystallization of a salt of a weak organic acid and base: Solubility relations, supersaturation control and polymorphic behavior. J. Phys. Chem. B, 2005, 109, 5273-8.
192. Park, H.J.; Kim, M.S.; Lee, S.; Kim, J.S.; Woo, J.S.; Park, J.S.; Hwang, S.J. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process. Int. J. Pharm., 2007, 328, 152-60.
193. Kariuki, B.M.; Psallidas, K.; Harris, K.D.M.; Johnston, R.L.; Lancaster, R.W.; Staniforth, S.E.; Cooper, S.M. Structure determination of a steroid directly from powder diffraction data. Chem. Commun., 1999, 1677-8.
194. Tanoury, G.J.; Hett, R.; Kessler, D.W.; Wald, S.A.; Senanayake, C.H. Taking advantage of polymorphism to effect an impurity removal: Development of a thermodynamic crystal form of (R,R)-formoterol tartrate. Org. Process Res. Dev., 2002, 6, 855-62
195. Cashell, C.; Corcoran, D.; Hodnett, B.K. Effect of amino acid additives on the crystallization of L-glutamic acid. Cryst. Growth Des., 2005, 5, 593-7.
196. Cox, J.R.; Ferris, L.A.; Thalladi, V.R. Selective growth of a stable drug polymorph by suppressing the nucleation of corresponding metastable polymorphs. Angew. Chem. Int. Ed., 2007, 46, 4333-6.
197. Price, C.P.; Grzesiak, A.L.; Lang, M.; Matzger, A.J. Polymorphism of nabumetone. Cryst. Growth Des., 2002, 2, 501-3
198. Caira, M.R.; Robbertse, Y.; Bergh, J.J.; Song, M.N.; de Villiers, M.M. Structural characterization, physicochemical properties, and thermal stability of three crystal forms of nifedipine. J. Pharm. Sci., 2003, 92, 2519-33.
199. Griesser, U.J.; Jetti, R.K.R.; Haddow, M.F.; Brehmer, T.; Apperley, D.C.; King, A.; Harris, R.K. Conformational polymorphism in oxybuprocaine hydrochloride. Cryst. Growth Des., 2008, 8, 44-56.
200. Lancaster, R.W.; Karamertzanis, P.G.; Hulme, A.T.; Tocher, D.A.; Lewis, T.C.; Price, S.L. The polymorphism of progesterone: Stabilization of a 'disappearing' polymorph by co-crystallization. J. Pharm. Sci., 2007, 96, 3419-31.
201. Miller, J.M.; Collman, B.M.; Greene, L.R.; Grant, D.J.W.; Blackburn, A.C. Identifying the stable polymorph early in the drug discovery-development process. Pharm. Dev. Technol., 2005, 10, 291-7.
202. Morissette, S.L.; Soukasene, S.; Levinson, D.; Cima, M.J.; Almarsson, Ö. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. PNAS, 2003, 100, 2180-4.
203. Tong, H.H.Y.; Shekunov, B.Y.; York, P.; Chow, A.H.L. Influence of operating temperature and pressure on the polymorphic transition of salmeterol xinafoate in supercritical fluids. J. Pharm. Sci., 2008, 97, 1025-9.
204. Sato, K.; Boistelle, R. Stability and occurrence of polymorphic modifications of stearic acid in polar and nonpolar solutions. J. Cryst. Growth, 1984, 66, 441-50.
205. Gu, C.H.; Chatterjee, K.; Young, V.; Grant, D.J.W. Stabilization of a metastable polymorph of sulfamerazine by structurally related additives. J. Cryst. Growth, 2002, 235, 471-81.
206. Parmar, M.M.; Khan, O.; Seton, L.; Ford, J.L. Polymorph selection with morphology control using solvents. Cryst. Growth Des., 2007, 7, 1635-42.
207. Lee, T.; Hung, S.T.; Kuo, C.S. Polymorph farming of acetaminophen and sulfathiazole on a chip. Pharm. Res., 2006, 23, 2542-55.
208. De Ilarduya, M.C.T.; Martin, C.; Goni, M.M.; Martínez-Ohárriz, M.C. Polymorphism of sulindac: Isolation and characterization of a new polymorph and three new solvates. J. Pharm. Sci., 1997, 86, 248-51.
209. Sonoda, Y.; Hirayama, F.; Arima, H.; Yamaguchi, Y.; Saenger, W.; Uekama, K. Selective crystallization of the metastable form IV polymorph of tolbutamide in the presence of 2,6-di-O-methyl-beta-cyclodextrin in aqueous solution. Cryst. Growth Des., 2006, 6, 1181-5.
210. Olives, A.I.; Martin, M.A.; del Castillo, B.; Barba, C. Influence of the presence of trace amounts of metals on the polymorphism of tolbutamide. J. Pharm. Biomed. Anal., 1996, 14, 1069-76.
211. 2 as antisolvent. J. Cryst. Growth, 2007, 309, 76-85.
212. Roy, S.; Bhatt, P.M.; Nangia, A.; Kruger, G.J. Stable polymorph of venlafaxine hydrochloride by solid-to-solid phase transition at high temperature. Cryst. Growth Des., 2007, 7, 476-80
213. Phadnis, N.V.; Suryanarayanan, R. Polymorphism in anhydrous theophylline: Implications on the dissolution rate of theophylline tablets. J. Pharm. Sci., 1997, 86, 1256-63.
214. Otsuka, M.; Matsuda, Y. Effects of environmental temperature and compression energy on polymorphic transformation during tableting. Drug Dev. Ind. Pharm., 1993, 19, 2241-69.
215. O'Brien, L.E.; Timmins, P.; Williams, A.C.; York, P. Use of in situ FT-Raman spectroscopy to study the kinetics of the transformation of carbamazepine polymorphs. J. Pharm. Biomed. Anal., 2004, 36, 335-40.
216. Ke, X.; Ping, Q.N.; Shi, H. Interconversion studies of betamethasone acetate polymorphs. Drug Dev. Ind. Pharm., 2005, 31, 813-8.
217. Zeitler, J.A.; Newnham, D.A.; Taday, P.F.; Threlfall, T.L.; Lancaster, R.W.; Berg, R.W.; Strachan, C.J.; Pepper, M.; Gordon, K.C.; Rades, T. Characterization of temperature-induced phase transitions in five polymorphic forms of sulfathiazole by terahertz pulsed spectroscopy and differential scanning calorimetry. J. Pharm. Sci., 2006, 95, 2486-98.
218. Nývlt, J. On the kinetics of solid-liquid-solid phase transformation. Cryst. Res. Technol., 1997, 32, 695-9.
219. Wang, F.; Wachter, J.A.; Antosz, F.J.; Berglund, K.A. An investigation of solvent mediated polymorphic transformation of progesterone using in situ Raman spectroscopy. Org. Process Res. Dev., 2000, 4, 391-5.